Search Results

Showing 85 results

Taxonomy / Categories

iwCLL 2025

Congress Year

International Workshop on CLL 2025

CLL

Disease Area

CLL/SLL

Disease Area

CLL

Congress Disease State

CLL/SLL

Congress Disease State

R/R CLL

Congress Disease State

Treatment Naive CLL/SLL

Congress Disease State

Real-world zanubrutinib treatment patterns in CLL/SLL among US community oncology patients with prior acalabrutinib therapy

Congress Presentation

Real-world zanubrutinib treatment patterns in CLL/SLL among US community oncology patients with prior acalabrutinib therapy

Real-world comparative analysis of treatment discontinuation with covalent Bruton tyrosine kinase inhibitors in first-line chronic lymphocytic leukemia (CLL)

Congress Presentation

Real-world comparative analysis of treatment discontinuation with covalent Bruton tyrosine kinase inhibitors in first-line chronic lymphocytic leukemia (CLL)

Treatment burden among patients (pts) aged 75 or older with chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL)

Congress Presentation

Treatment burden among patients (pts) aged 75 or older with chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL)

Real-world impact of atrial fibrillation (AFib) on cardiovascular (CV) outcomes and healthcare resource utilization (HCRU) in patients with chronic lymphocytic leukemia (CLL)

Congress Presentation

Real-world impact of atrial fibrillation (AFib) on cardiovascular (CV) outcomes and healthcare resource utilization (HCRU) in patients with chronic lymphocytic leukemia (CLL)

Changes in real-world treatment patterns over time by patient characteristics and time burden of treatment in CLL/SLL

Congress Resource

Treatment patterns and outcomes among patients treated with second-generation BTK inhibitors in CLL

Congress Resource

Patient preferences and factors affecting patient treatment decisions for chronic lymphocytic leukemia (CLL) in Japan

Congress Resource

Real-world treatment patterns and biomarker utilization among patients aged ≥65 years with CLL/SLL from 2020 to 2024

Congress Resource

A phase 3, randomized, open-label, multicenter study of sonrotoclax (BGB-11417) plus anti-CD20 antibody therapies vs venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL-RR1/CELESTIAL-RRCLL)

Congress Resource

Evaluation of factors from established prognostic models in patients with chronic lymphocytic leukemia (CLL) treated with zanubrutinib: A post-hoc analysis of two phase 3 studies (SEQUOIA and ALPINE)

Congress Resource

You are now leaving the website

This link is provided for information purposes only. You’ll be leaving beonemedaffairs.com and accessing a third-party website over which [BeOne Medicines | GmbH] has no control or influence.

This link will take you to a third-party website outside of beonemedaffairs.com.

[BeOne Medicines | GmbH] has no control over this website and makes no representations regarding its content or availability in your location. [BeOne Medicines | GmbH] declines any responsibility for third-party information, data usage policies, or personal data processing.

By proceeding, you acknowledge that you are part of the intended audience of the third-party website and confirm your compliance with applicable laws.

Do you want to leave beonemedaffairs.com

You are now leaving the the website beonemedaffairs.com and entering another BeOne website with different terms of use. Information included on this website may not be specific to your country. Click Continue to proceed